Keywords: erbitux, sets, new, record, rmscchn, survival, anti-egfr

Erbitux sets new record for RMSCCHN survival

Article | 11 June 2007

Print This

The anti-EGFR targeted cancer therapy Erbitux (cetuximab), developed by Merck KGaA in Europe and by Bristol-Myers Squibb and Imclone in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in